思略特：2025年GLP-1类药物对对医疗科技行业的战略影响研究报告（英文版）

Glucagon-like-Peptide-1 (GLP-1) has attracted enormous attention over recent years due to its effectiveness in aiding weight loss, and in treating and inducing remission of type 2 diabetes mellitus. Further emerging use cases for GLP-1, for example in the treatment of chronic kidney disease and in certain types of addiction, have only amplified this attention. Given this rapid rise to prominence, GLP-1s such as Wegovy and Mounjaro may now constitute one of the most significant—and disruptive—